Compare ADMA Biologics Inc (ADMA) vs Okta, Inc. (OKTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Okta, Inc. — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Okta, Inc. trades at $145.77 (market cap $25.81B). The key difference: Okta, Inc. is far larger — about 12.1× ADMA Biologics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | OKTA | |
|---|---|---|
Market Cap | $2.13B | $25.81B |
Sector | Health | Technology |
52-Week High | $20.38 | $148.60 |
52-Week Low | $7.60 | $62.93 |
Enterprise Value | $2.20B | $23.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
OKTA trades at $148.47, up 4.99% on the day, with strong technical momentum and bullish moving averages. The company reported revenue of $2.61B in 2025, achieving profitability with net income of $28M after years of losses. Recent earnings beats and AI-driven demand have fueled investor optimism, though valuation multiples remain elevated.
Outlook is positive with robust revenue growth and improving margins, but high P/E of 107.68 poses valuation risk. Analyst consensus is bullish with 72.55% buy ratings, though price target of $121.08 suggests caution near current levels. Key risks include competition and execution on AI monetization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
